|Mr. Joseph P. Hagan M.B.A.||Pres, CEO, Interim CFO & Director||758.25k||N/A||1969|
|Mr. Daniel R. Chevallard||Exec. Officer||448.33k||N/A||1980|
|Mr. Daniel Penksa||Controller & Principal Accounting Officer||N/A||N/A||1985|
|Mr. Christopher Ray Aker J.D.||Sr. VP. Gen. Counsel & Corp. Sec.||N/A||N/A||1961|
|Mr. Turner Jenkins||Sr. Director of Corp. Devel.||N/A||N/A||N/A|
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products, which include RGLS5579 to inhibit miR-10b, and Hepatitis B virus program and Non-Alcoholic Steatohepatitis program. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
Regulus Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.